Drugs /

vismodegib

Back to Drugs List
Associated Genetic Biomarkers
Associated Diseases

Overview

Generic Name(s):
vismodegib
Trade Name(s):
Erivedge
NCI Definition [1]:
An orally bioavailable small molecule with potential antineoplastic activity. Hedgehog antagonist GDC-0449 targets the Hedgehog signaling pathway, blocking the activities of the Hedgehog-ligand cell surface receptors PTCH and/or SMO and suppressing Hedgehog signaling. The Hedgehog signaling pathway plays an important role in tissue growth and repair; aberrant constitutive activation of Hedgehog pathway signaling and uncontrolled cellular proliferation may be associated with mutations in the Hedgehog-ligand cell surface receptors PTCH and SMO.

Biomarker-Directed Therapies

Clinical Trials

View Clinical Trials for vismodegib

Vismodegib has been investigated in 9 clinical trials, of which 7 are open and 2 are closed. Of the trials investigating vismodegib, 1 is phase 1 (1 open), 7 are phase 2 (5 open), and 1 is phase 4 (1 open).

PTCH1 Loss, PTCH1 Mutation, and SMO Mutation are the most frequent biomarker inclusion criteria for vismodegib clinical trials.

Malignant solid tumor, acute myeloid leukemia, and basal cell carcinoma are the most common diseases being investigated in vismodegib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Vismodegib
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Vismodegib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating vismodegib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
gdc-0449, Erivedge, hedgehog antagonist gdc-0449, gdc0449, vismodegib (product), gdc 0449, vismodegib (substance), hedgehog antagonist gdc-0449, vismodegib, vismodegibum, 2-chloro-n-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide, vismodegib, erivedge
Drug Categories [2]:
SMO inhibitors
Drug Target(s) [2]:
SMO
NCIT ID [1]:
C74038
SNOMED ID [1]:
R-FBDCC

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.